Home › Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research
 

Keywords :   


Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research

2016-04-09 14:25:16| Biotech - Topix.net

The firm presently has a $1.25 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 9.65% from the company's previous close.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.09Washington Corner | September 2024
27.09Hurricane Isaac Graphics
27.09Remnants of John Graphics
27.09Remnants of John Forecast Discussion Number 20
27.09Remnants of John Wind Speed Probabilities Number 20
27.09Remnants of John Public Advisory Number 20
27.09Summary for Remnants of John (EP5/EP102024)
27.09Tropical Storm Joyce Graphics
More »